NASDAQ:IMMX Immix Biopharma Q3 2026 Earnings Date & Estimates $9.46 +0.17 (+1.83%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$9.45 -0.01 (-0.11%) As of 10/9/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immix Biopharma is expected to report Q3 2026 earnings on Friday, November 6, 2026. The conference call is scheduled for November 10, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 6, 2026Conference Call DateNovember 10, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Immix Biopharma in Q3 2026Immix Biopharma is expected to post earnings of -$0.19 per share. In the same quarter a year earlier Immix Biopharma reported -$0.24 per share. Immix Biopharma last reported on August 7, 2026, posting -$0.18 per share and missing the -$0.17 consensus estimate. Immix Biopharma has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.19Prior-Year EPS-$0.24Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.18 (Missed by -$0.01)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Immix Biopharma Q3 2026 Earnings FAQ When does Immix Biopharma report Q3 2026 earnings? Immix Biopharma (NASDAQ:IMMX) is estimated to report Q3 2026 earnings on Friday, November 6, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Immix Biopharma's Q3 2026 earnings call? Immix Biopharma's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Immix Biopharma? Analysts expect Immix Biopharma to post earnings of -$0.19 per share for Q3 2026. Immix Biopharma Earnings HeadlinesImmix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceOctober 5, 2026 | globenewswire.comImmix Biopharma consensus price target increased by 10.16% to $25.04October 2, 2026 | msn.comA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, and predictions. He argues a simpler approach can work just as well. His free report, The Simple Path To Success With Options, breaks down a repeatable trade setup, common rookie mistakes, and step-by-step blueprints designed to cut through market noise. No complex charts. No guesswork. Just a straightforward setup anyone can learn.October 10 at 1:00 AM | TradeWins (Ad)Immix Biopharma (NASDAQ:IMMX) Sees Strong Trading Volume After Analyst UpgradeOctober 1, 2026 | americanbankingnews.comImmix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Needham & Company LLC Analyst SaysOctober 1, 2026 | americanbankingnews.comImmix Biopharma Closes $125 Million Stock OfferingSeptember 30, 2026 | finance.yahoo.comSee More Immix Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immix Biopharma and other key companies, straight to your email. Email Address About Immix BiopharmaImmix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer and autoimmune diseases. The company’s research centers on treatments designed to use a patient’s immune system to identify and attack disease-related cells. Its lead product candidate is NXC-201, an investigational autologous CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on malignant plasma cells. NXC-201 is being evaluated in clinical studies involving patients with relapsed or refractory AL amyloidosis and multiple myeloma, including the company’s NEXICART-1 study. Immix Biopharma was founded in 2012 and is based in Los Angeles, California. The company conducts development activities and clinical research in the United States and Australia. Its leadership includes founder and Chief Executive Officer Ilya Rachman, who has overseen the company’s efforts to advance its cellular-therapy pipeline.View Immix Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
